REG - Haleon PLC - Transaction in Own Shares

HALEONAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250801:nRSA5002Ta&default-theme=true

RNS Number : 5002T  Haleon PLC  01 August 2025

 

Haleon plc: Transaction in own shares

 

01 August 2025: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 881,993 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under the second tranche of its share buyback
programme announced on 31 July 2025.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE
 Date of purchase:                                  31 July 2025           31 July 2025   31 July 2025
 Number of Shares purchased:                        881,993                -              -
 Highest price paid per Share (p):                  364.7000               -              -
 Lowest price paid per Share (p):                   347.0000               -              -
 Volume weighted average price paid per Share (p):  360.1289               -              -

 

Following the settlement of the above, the Company's registered share capital
is 8,987,651,560 ordinary shares of £0.01 each, of which 3,880,205 are held
as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,983,771,355 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/5002T_1-2025-7-31.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/5002T_1-2025-7-31.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSDFLFXEDLFBBZ